Condition

NSCLC

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 388 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials388

Recruiting79

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCNCT07158489 · 2026-08-21

Study of NXP900 With Lorlatinib in ALK+ Lung CancerNCT07784959 · 2026-08-17

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCNCT07777822 · 2026-08-14

SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerNCT07697586 · 2026-08-07

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCNCT07671092 · 2026-06-15

Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+ChemoNCT07612722 · 2026-05-18

Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLCNCT07479277 · 2026-02-27

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338 · 2026-01-30

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot StudyNCT07412041 · 2026-01-22

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · 2026-01-08

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung DiseaseNCT07323732 · 2026-01-06

Molecular Phenotyping of Primitive Lung Cancer and Metastatic SiteNCT07325864 · 2025-12-18

HC010 in First-line PD-L1 Positive Advanced NSCLC PatientsNCT07169552 · 2025-12-09

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant ChemoimmunotherapyNCT07330037 · 2025-12-01

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）NCT07388771 · 2025-12-01

YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)NCT07793500 · 2025-11-27

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · 2025-11-19

A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerNCT07647094 · 2025-11-01

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNCT07182149 · 2025-10-30

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung CancerNCT06671613 · 2025-10-27

RGL-270 + ICI in Advanced NSCLCNCT07652125 · 2025-10-25

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung CancerNCT07082179 · 2025-09-04

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKINCT07181499 · 2025-09-01

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer PatientsNCT07138755 · 2025-08-29

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerNCT06865339 · 2025-08-07

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II StudyNCT07089199 · 2025-07-25

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisNCT06315010 · 2025-06-27

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibNCT06620835 · 2025-06-19

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsNCT06922591 · 2025-05-31

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)NCT06462963 · 2025-04-15

BBO-11818 in Adult Subjects With KRAS Mutant CancerNCT06917079 · 2025-03-31

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung CancerNCT05798845 · 2025-02-20

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCNCT06864624 · 2025-02-18

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung CancerNCT06738160 · 2025-02-15

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)NCT06731413 · 2025-02-11

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsNCT06789172 · 2025-01-23

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCNCT06754644 · 2025-01-15

Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung TumorsNCT06739031 · 2024-12-25

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic PatientsNCT06576635 · 2024-12-16

First in Human Study of TUB-030 in Patients With Advanced Solid TumorsNCT06657222 · 2024-12-13

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung CancerNCT06457789 · 2024-12-01

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLCNCT06714708 · 2024-11-20

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyNCT06362369 · 2024-08-23

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesNCT06248606 · 2024-08-06

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLCNCT06532591 · 2024-08-01

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyNCT06534762 · 2024-07-15

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally AdvancedNCT06467383 · 2024-06-25

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143 · 2024-06-10

Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic PotentialNCT06807307 · 2024-06-04

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerNCT06343402 · 2024-05-22

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerNCT06431685 · 2024-04-25

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionNCT06051695 · 2024-04-03

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangementsNCT05987644 · 2024-03-07

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II StudyNCT07085182 · 2024-01-13

A Study of YL202 in Selected Patients With Advanced Solid TumorsNCT06107686 · 2023-12-15

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLCNCT06142058 · 2023-11-13

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)NCT06116019 · 2023-10-11

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCNCT07247227 · 2023-10-10

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsNCT06043817 · 2023-09-26

Common interventions

Leading sponsors

Shanghai Chest Hospital 7 Tianjin Medical University Cancer Institute and Hospital 7 Allist Pharmaceuticals, Inc. 5 AstraZeneca 5 Fudan University 5 Maastricht Radiation Oncology 5 Memorial Sloan Kettering Cancer Center 5 Pfizer 5 Shanghai Pulmonary Hospital, Shanghai, China 5 The First Affiliated Hospital of Guangzhou Medical University 5 TYK Medicines, Inc 5 A2 Biotherapeutics Inc. 4 Guangdong Association of Clinical Trials 4 Revolution Medicines, Inc. 4 Spectrum Pharmaceuticals, Inc 4

Trial status mix

UNKNOWN89

COMPLETED87

RECRUITING79

TERMINATED45

NOT_YET_RECRUITING40

ACTIVE_NOT_RECRUITING33

WITHDRAWN11

ENROLLING_BY_INVITATION2

SUSPENDED2

Phase mix

PHASE2189

PHASE194

PHASE338

NA37

PHASE49

EARLY_PHASE15

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.